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Abstract: In humans, structural and functional changes attributable to aging are more visibly 
evident in the skin than in any other organ. Estrogens have signiﬁ  cant effects on skin physiol-
ogy and modulate epidermal keratinocytes, dermal ﬁ  broblasts and melanocytes, in addition to 
skin appendages including the hair follicle and the sebaceous gland. Importantly, skin aging 
can be signiﬁ  cantly delayed by the administration of estrogen. This paper reviews the effects 
of estrogens on skin and the mechanisms by which estrogens can alleviate the changes due to 
aging that occur in human skin. The relevance of estrogen replacement therapy (HRT) in post-
menopausal women and the potential value of selective estrogen receptor modulators (SERMs) 
as a therapy for diminishing skin aging are also highlighted.
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Estrogens and skin biology
A number of studies have shown that estrogens have many important beneﬁ  cial and 
protective roles in skin physiology (reviewed in Thornton 2002, 2005). They have 
been shown to accelerate cutaneous wound healing (Ashcroft and Ashworth 2003), 
while a signiﬁ  cant number of women notice an improvement in inﬂ  ammatory skin 
disorders such as psoriasis during pregnancy (Dunna and Finlay 1989; Boyd et al 1996; 
Raychaudhuri et al 2003). Estrogens also offer some degree of protection against skin 
photoaging (Weinstock 1994; Tsukahara et al 2001, 2004) and epidemiological studies 
indicate that the mortality rates from both non-melanoma skin cancers (Weinstock 
1994) and melanoma (Miller and MacNeil 1997) are signiﬁ  cantly lower in women. 
Many of the effects of estrogen on human skin are based on the changes that are 
seen in post-menopausal women, with a number of studies documenting the differences 
seen following the menopause, although there is also a variation in skin thickness during 
the menstrual cycle, with skin thickness lowest at the start of the menstrual cycle, when 
estrogen and progesterone levels are low, which then increases with the rising levels of 
estrogen (Eisenbeiss 1998). Many women report a sudden onset of skin aging several 
months after menopausal symptoms begin. The menopause causes hypoestrogenism, 
accelerating age-related deterioration, which results in thinner skin, an increase in 
number and depth of wrinkles, increased skin dryness, and decreased skin ﬁ  rmness 
and elasticity (Brincat 2000). Hormone replacement therapy (HRT) has been shown 
to increase epidermal hydration, skin elasticity, skin thickness (Sator et al 2001), and 
also reduces skin wrinkles (Phillips et al 2001). Furthermore, the content and quality 
of collagen and the level of vascularization is enhanced (Brincat et al 1987). 
The epidermis 
Epidermal thinning is associated with aging, and topical estradiol has been shown 
to reduce epidermal thinning in aging skin and maintain skin thickness (Shah and 
Maibach 2001). Recent studies have conﬁ  rmed that administration of estradiol to Clinical Interventions in Aging 2007:2(3) 284
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gonadectomised mice increases epidermal thickness in both 
sexes (Azzi et al 2005). 
In women an increase in the mitotic activity of epidermal 
keratinocytes occurs in response to estrogens (Punnonen 
1972). Furthermore, the stimulation of proliferation and DNA 
synthesis of human epidermal keratinocytes by estrogens has 
been demonstrated in vitro (Urano et al 1995; Kanda and 
Watanabe 2004; Verdier-Sevrain et al 2004) and cultured 
human epidermal keratinocytes have high afﬁ  nity estrogen 
binding sites (Verdier-Sevrain et al 2004). Speciﬁ  c antibodies 
for the two distinct intracellular estrogen receptors (ERα and 
ERβ) have shown that epidermal keratinocytes from human 
scalp skin of both sexes predominately express ERβ in situ 
(Thornton et al 2003). 
However, primary cultures of epidermal keratinocytes 
from female breast skin express both ERα and ERβ in vitro 
(see Figure 1). 
Another study has demonstrated mRNA and protein for 
ERβ and not ERα is expressed in cultured human epidermal 
keratinocytes (Kanda and Watanabe 2003a, 2003b), while 
a different group have shown that both ERα and ERβ are 
expressed in cultured human neonatal foreskin keratinocytes 
(Verdier-Sevrain et al 2004). These differences may be due to 
differences in anatomical site, since the number of estrogen 
receptors has been shown to differ with anatomical site, with 
face skin homogenates having a greater number of receptors 
than breast or thigh skin (Hasselquist et al 1980). A more 
recent study has shown that there are marked differences in 
the expression of the two estrogen receptors in human skin 
derived from different anatomical sites including scalp, breast 
and abdomen (Nelson 2006); in contrast to scalp, which pre-
dominantly expresses ERβ (Thornton et al 2003), breast skin 
predominantly expresses ERα in situ (Nelson 2006).
Recently, it has been reported that 17β-estradiol con-
jugated with BSA can stimulate proliferation and DNA 
synthesis of cultured human keratinocytes (Kanda and 
Watanabe 2004), suggesting that estradiol can stimulate cell 
proliferation via a cell membrane receptor. This is further 
supported by another group who demonstrated that incuba-
tion of cultured human epidermal keratinocytes with estradiol 
increased phosphorylation levels of ERK1 and ERK2 kinases 
within 15 minutes (Verdier-Sevrain et al 2004). 
A protective role for estrogens on the human epidermis 
may also exist since estradiol prevents apoptosis induced 
by hydrogen peroxide in cultured epidermal keratinocytes 
by promoting the expression of bcl-2 (Kanda and Watanabe 
2003a). Furthermore, estradiol inhibits the production of 
chemokines involved in the attraction of macrophages, 
which are important in inﬂ  ammation (Kanda and Watanabe 
2003b).
The dermis
Autoradiography following administration of systemic or 
topical estrogen has demonstrated that radio-labeled estradiol 
binds to dermal ﬁ  broblasts in rat and mouse skin (Stumpf 
et al 1974; Bidmon et al 1990). More recently, speciﬁ  c 
antibodies have demonstrated ERβ, but not ERα is expressed 
by dermal ﬁ  broblasts in the papillary dermis of human scalp 
skin in both sexes (Thornton et al 2003), whereas primary 
cultures of human dermal ﬁ  broblasts from female skin have 
been shown to express both mRNA and protein for ERα and 
ERβ (Haczynski et al 2002). Although dermal ﬁ  broblasts 
co-express both estrogen receptors, immunocytochemistry 
showed some variation in their expression; ERβ was pre-
dominately nuclear, while ERα was expressed in both the 
cytoplasm and the nucleus. Furthermore, mRNA levels for 
ERβ were higher than levels of ERα. A later study by the 
same group has demonstrated that estradiol up-regulates 
the expression of ERβ in dermal ﬁ  broblasts cultured from 
postmenopausal women (Surazynski et al 2003), thereby 
altering the ratio of ERα to ERβ. 
Estrogens have been shown to inﬂ  uence skin thickness 
by stimulating collagen synthesis, maturation and turnover 
in rats (Smith and Allison 1966) and female guinea pigs 
(Henneman 1968). In mice, estrogen administration increased 
hyaluronic acid synthesis by 70% in two weeks (Sobel 1965), 
leading to increased dermal water content. In wound healing 
models, estrogen reduces wound size and stimulates matrix 
ERα       E R β
Figure 1 The expression of ERα and ERβ in human epidermal keratinocytes cul-
tured from human female breast skin. Both nuclear and cytoplasmic expression of 
ERα and ERβ, with intense staining in the perinuclear region was seen in epidermal 
keratinocytes derived from female breast skin.Clinical Interventions in Aging 2007:2(3) 285
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deposition in both human and murine skin (Ashcroft et al 
1999; Ashcroft and Ashworth 2003), highlighting the effects 
of estrogens on the dermal ﬁ  broblasts. 
Estrogen is also believed to provide some protection 
against photoaging. Ultraviolet (UV)-B exposure is associ-
ated with up-regulation of matrix metalloproteinase (MMP) 
production, leading to an increase in collagen degradation 
and is also thought to decrease type I and type III collagen 
synthesis (reviewed in Baumann 2005). Tsukahara and col-
leagues (2001) demonstrated that ovariectomized rats exposed 
to UVB radiation display an increased formation of deep 
wrinkles, decreased skin elasticity and marked and advanced 
curling of dermal elastic ﬁ  bers compared to rats with normal 
estrogen levels. Furthermore, the same authors demonstrated 
that in hairless mice ovariectomy alone decreases skin elas-
ticity, with a further signiﬁ  cant increase in skin sagging in 
the ovariectomized animals exposed to 12 weeks of UV-A 
irradiation and a signiﬁ  cant increase in skin wrinkling fol-
lowing UV-B irradiation (Tsukahara et al 2004). In each case 
this was associated with an increase in elastase activity. This 
led the authors to suggest that ovariectomy causes an increase 
in elastase mediated degradation of dermal elastic ﬁ  bers with 
a subsequent reduction in skin elasticity, thus explaining the 
skin changes seen in post-menopausal women. 
In vitro, murine dermal ﬁ  broblasts have been shown to 
increase collagen synthesis by 76% in response to estrogen 
(Hosokawa et al 1981). Similarly, incubation of cultured 
human dermal ﬁ  broblasts with 17β-estradiol increased type 
I procollagen secretion (Son et al 2005). This effect was 
reversed when estrogen was administered with TGF-β1 anti-
bodies, suggesting that TGF-β1 may play a role in increasing 
collagen secretion in response to estrogen. Other authors have 
also demonstrated an increase in collagen biosynthesis in 
vitro in response to 17β-estradiol by measuring radio-labeled 
proline incorporation (Surazynski et al 2003). 
The hair follicle
Hair follicles have a built in rhythm of activity that results 
in the periodic regeneration of new hairs and the molting 
of old ones. This rhythm appears to be intrinsic, although 
it can be inﬂ  uenced by hormonal or other systemic fac-
tors. Estrogens signiﬁ  cantly inﬂ  uence the hair cycle in a 
number of mammalian species by inhibiting hair growth 
(reviewed in Thornton 2002, 2005; Ohnemus et al 2006). 
However, the effects of estrogens on the human hair cycle 
are less clear. 
In contrast to the inhibition observed in other mammals, 
limited studies suggest that estrogens may have a stimula-
tory effect on human hair growth. During pregnancy there 
is an increase in the ratio of hair follicles in the growing 
phase of the cycle; after parturition, these follicles enter the 
resting phase, resulting in increased hair shedding and a 
transient thinning of the hair (Lynﬁ  eld 1960). These events 
have been ascribed to the changes in the level of circulating 
estrogen during, and immediately following pregnancy. 
However, it is difﬁ  cult to accredit this phenomenon entirely 
to the rise in plasma estrogen as several other hormones and 
growth factors that modulate hair growth are also altered 
at this time. 
There is some limited trichogram data to suggest that 
estrogens decrease the resting phase and prolong the growing 
phase of the hair cycle, hence estrogens are used in the treat-
ment of female pattern hair loss in some countries (Sinclair 
1999). Further evidence for a stimulatory effect of estrogens 
on human hair growth comes from the treatment of women 
with tamoxifen which may result in scalp hair thinning 
or recession in some women (Gateley and Bundred 1997; 
Ayoub et al 1997). Likewise, a common treatment-related 
side effect of aromatase inhibitors, which inhibit the synthesis 
of estrogen, is scalp hair thinning in women (Buzdar et al 
2001; Simpson et al 2004). 
Recent in vitro studies have shown that 17β-estradiol 
inhibits female scalp hair shaft elongation (Nelson 2006), 
although stimulation occurs in hair follicles derived from 
frontotemporal male scalp (Conrad et al 2004; Conrad and 
Paus 2004). In addition, in female hair follicles the phytoes-
trogen, genistein inhibits hair shaft elongation to a similar 
extent as 17β-estradiol. Since genistein preferentially binds 
to ERβ, this opens the possibility that the inhibition of hair 
growth in response to 17β-estradiol may be mediated via ERβ 
rather than ERα (Nelson 2006). Therefore the development 
of selective estrogen receptor ligands may provide important 
clinical applications for the prevention and treatment of 
disorders of hair growth. 
Melanocytes and melanoma
Chloasma is a common hyperpigmentation of the face seen 
in pregnant women, often accompanied by increased pig-
mentation in other areas including the areolae, linea alba and 
perineal skin, all of which usually fade following parturition 
(Kroumpouzos and Cohen 2001). Oral contraceptives con-
taining estrogen can also result in hyperpigmentation of the 
face (Wade et al 1978) and ointments containing estrogen 
can produce intense pigmentation of the genitals, mammary 
areola and linea alba of the abdomen in male and female 
infants (Beas et al 1969). Clinical Interventions in Aging 2007:2(3) 286
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The mean age of presentation of malignant melanoma in 
women is the early ﬁ  fties, which correlates with the onset of 
the menopause (Durvasula et al 2002). Melanoma has tradi-
tionally been considered to be an estrogen receptor-positive 
tumor, whose prognosis is adversely affected by estrogen, 
whether during pregnancy or in association with the oral 
contraceptive pill or HRT. Recent evidence now disputes 
this and the relationship between estrogens and malignant 
melanoma remains controversial. 
There is a signiﬁ  cant lack of information in relation to 
HRT and melanoma and the use of steroid hormones in 
the management of melanoma is limited. Steroid hormone 
binding activity has been demonstrated in some human 
melanomas, but only a small percentage of melanomas 
respond to hormonal manipulation (Neifeld 1996). The 
relative expressions of the different estrogen receptors in 
malignant melanoma have yet to be explored, which may 
be of signiﬁ  cance since alterations in the ratio of ERα and 
ERβ have been suggested in the development and progres-
sion of other cancers. 
The menopause
Post-menopausal skin has been shown to have increased 
dryness (Sator et al 2004), decreased elasticity (Henry et al 
1997; Sumino et al 2004), and increased wrinkling (Dunn 
et al 1997). Indeed, many of the effects of estrogen on the 
human skin have been described based on the changes that 
are seen following the menopause. Estrogen receptor expres-
sion has been shown to be reduced following the menopause 
(Punnonen et al 1980; Nelson and Bulun 2001). 
In postmenopausal women skin thickness decreases by 
1.13% per postmenopausal year, with an associated decrease 
in collagen content (2% per post-menopausal year) (Brincat 
et al 1987). The collagen content (types I and III) of skin is 
thought to decrease by as much as 30% in the ﬁ  rst ﬁ  ve years 
following the menopause (Brincat et al 1985; Afﬁ  nito et al 
1999). Interestingly, this decrease in skin collagen content 
parallels the reduction in bone mass seen in post-menopausal 
women (Brincat et al 1987). The decrease in skin thickness 
and collagen content seen in elderly females appears to 
correlate more closely with the period of estrogen deﬁ  -
ciency than with chronological age (Brincat et al 1985, 1987; 
Afﬁ  nito et al 1999). 
In contrast, another study has demonstrated a closer 
relationship between chronological age and reduction in 
skin collagen, than time since menopause (Castelo-Branco 
et al 1992). However, for the patients in this study the 
time spent post-menopause was much shorter, therefore 
the long-term effects of estrogen deﬁ  ciency may not have 
become apparent. 
A difference in collagen subtypes has also been docu-
mented in post-menopausal women. When evaluated by 
immunohistochemistry, compared to pre-menopausal 
women, post-menopausal women demonstrate a decrease in 
collagen types I and III and a reduction in the typeIII/type I 
ratio within the dermis. Again this correlates more closely 
with period of estrogen deﬁ  ciency than with chronological 
age (Afﬁ  nito et al 1999). Similar ﬁ  ndings have been reported 
in the arcus tendineous fasciae pelvis, where the collagen type 
I and type I/type III ratio was decreased in postmenopausal 
women compared to premenopausal women (Moalli et al 
2004). Interestingly, despite these changes the total amount 
of collagen was not altered. 
Hormone replacement therapy
Further understanding of estrogen effects on human skin is 
derived from comparisons between post-menopausal women 
taking estrogen replacement therapy and those who have 
not. An early study reported an increase in epidermal thick-
ness in human female skin in response to six months of oral 
estrogens (Punnonen 1972). Although a different study did 
not demonstrate an increase in epidermal thickness, Maheux 
et al (1994) demonstrated an increased keratinocyte volume 
and more deﬁ  ned rete ridges in response to oral estrogen. 
More recent studies have conﬁ  rmed that topical estrogen 
increases epidermal thickness (Son et al 2005; Patriarca 
et al 2007). Furthermore, Son et al (2005) demonstrated an 
increase in keratinocyte proliferation and epidermal thick-
ness in response to only two weeks of topical estrogen in the 
skin of elderly males and females. HRT has also been shown 
to improve skin hydration when estrogen is administered 
systemically (Pierard-Franchimont et al 1995) or topically 
(Sator et al 2001). Topical application is an efﬁ  cient method, 
since due to its small molecular size; estrogen easily pen-
etrates the stratum corneum (Draelos 2005). The increased 
hydration is believed to be due in part to an increase in the 
water-holding capacity of the stratum corneum (Pierard-
Franchimont et al 1995). Additionally, dermal hyaluronic 
acid and acid mucopolysaccharide levels are increased, 
which will also improve hydration (reviewed in Shah and 
Maibach 2001). 
In a randomized, double-blind, placebo-controlled trial, 
Maheux et al (1994), demonstrated that after 12 months 
of oral estrogen therapy, dermal thickness was increased 
by 30%, resulting in increased skin thickness in post-
menopausal nuns. Skin biopsies were taken from the thigh Clinical Interventions in Aging 2007:2(3) 287
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thus eliminating confounding factors such as sun exposure 
and smoking (Maheux et al 1994). Other authors have also 
demonstrated increased skin thickness following HRT (Brin-
cat et al 1985; Callens et al 1996; Sator et al 2001). 
In addition to increased skin thickness, estrogen has also 
been shown to increase the collagen content of the skin. A 
randomized, double-blind, placebo-controlled trial carried 
out by Sauerbonn et al (2000) demonstrated an increase of 
6.49% in skin collagen ﬁ  ber content after six months of treat-
ment with an oral combination of estrogen and cytoproterone 
acetate. Other authors have demonstrated an increase in 
overall collagen content (Brincat et al 1987) and speciﬁ  cally 
collagen type III (Savvas et al 1993; Schmidt et al 1996). 
Another study found no difference in skin thickness or 
collagen content in upper arm or abdominal skin following 
oral estrogen therapy (Haapasaari et al 1997); however the 
patients in this study had only a short period of estrogen 
deﬁ  ciency (median time post-menopause 12 months), which 
may explain this ﬁ  nding. Importantly, the increase in skin 
collagen content in response to estrogen therapy appears 
to be related to the initial collagen content. Brincat et al 
(1987) demonstrated that in women with low skin collagen 
content, estrogen is initially therapeutic, but later becomes 
purely prophylactic, whereas for women in the early years 
post-menopause with only mild collagen loss, estrogen is of 
prophylactic value only. Indeed, optimum collagen content 
was seen following two years of treatment in a study which 
examined the effect of estradiol implants over a period rang-
ing from two to ten years (Brincat et al 1987). 
The use of topical estrogen has also been shown to 
increase skin collagen. Varila et al (1995) demonstrated 
an increase in collagen content following topical estrogen 
administration. They also demonstrated an increase in col-
lagen synthesis as shown by increased type I and type III 
procollagen levels. However, with topical administration, 
the effect was limited to the area to which the estrogen was 
directly applied (Varila et al 1995; Schmidt et al 1996). A 
more recent study examining the effect of estrogen on human 
skin has demonstrated an increase in collagen content in but-
tock skin from elderly males and females treated with topical 
estradiol (Son et al. 2005). Type I procollagen mRNA and 
protein were signiﬁ  cantly increased in males and females, 
with a signiﬁ  cantly greater increase in females compared 
to males. Similarly, immunohistochemical expression for 
type I procollagen protein was increased following estradiol 
treatment. The same group also demonstrated an increase in 
tropoelastin and ﬁ  brillin mRNA and protein in response to 
estradiol and suggested this can be equated to an increase in 
elastic ﬁ  bers. Furthermore, they demonstrated an increase 
in TGF-β and TGF-β type II receptor mRNA and protein 
expression in response to estrogen therapy, although TGF-β 
type-I receptor expression was not increased. Since TGF-β 
is a growth factor known to stimulate ﬁ  broblast proliferation 
and extracellular matrix (ECM) secretion, they suggested 
that this is the mechanism by which estrogen increases 
ECM secretion (Son et al 2005). Furthermore, a decrease in 
MMP-1 expression was demonstrated in response to topical 
estrogen, which may also explain increased collagen content 
in estrogen treated skin. Interestingly, when topical estradiol 
was applied to the skin of young males, similar effects were 
also demonstrated (Son et al 2005).
Skin wrinkling is synonymous with aging, but is also 
affected by environmental and hormonal factors. It occurs 
due to decreased skin elasticity as a result of elastic degen-
eration and loss of connective tissue (reviewed in Shah and 
Maibach 2001). In early postmenopausal women monitored 
for ﬁ  ve years, skin elasticity has been shown to decrease by 
1.5% per year, a change not seen in women on HRT (Henry 
et al 1997). Furthermore, conjugated equine estrogen has 
been shown to increase forearm skin elasticity in postmeno-
pausal women (Sumino et al 2004). Punnonen et al (1987) 
demonstrated that topical estrogen thickens elastic ﬁ  bers in 
the papillary dermis, increases their number and improves 
their orientation, although this effect has not been shown by 
other authors (Brincat et al 2005). This led to the suggestion 
that estrogen deﬁ  ciency plays a role in wrinkle formation 
and in a large cohort study it was shown that wrinkling is 
reduced in postmenopausal women administered estrogen 
(Dunn et al 1997). 
In post-menopausal women skin wrinkling has also been 
shown to be improved by topical estrogen therapy after a 24-
week treatment period (Creidi et al 1994). However, other 
authors have demonstrated an improvement in skin elasticity, 
although there was no improvement in wrinkling in smokers 
(Castelo-Branco et al 1998). Furthermore, estrogen was not 
shown to consistently improve the appearance of facial skin 
over a ﬁ  ve-year period, suggesting the effects may be reduced 
in sun-exposed skin (Pierard-Franchimont et al 1999). 
More recently, Wolff et al (2005) demonstrated decreased 
facial wrinkling and increased skin rigidity following long-
term oral estrogen administration. Women who were at least 
ﬁ  ve years post-menopause and had either taken oral estrogen 
continuously, or had never used HRT, were examined by a 
single blind observer who assessed wrinkle formation us-
ing an objective photographic wrinkle score and measured 
skin rigidity using a durometer. They demonstrated that the Clinical Interventions in Aging 2007:2(3) 288
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average wrinkle score was signiﬁ  cantly lower in the hormone 
treated group. Skin rigidity was also signiﬁ  cantly lower in 
the group using HRT (Wolff et al 2005). This suggests that 
estrogen therapy has long-term beneﬁ  ts on skin and supports 
the use of early and continuous HRT in preventing detrimen-
tal skin changes (Naftolin 2005).
Although estrogen administration has been shown to have 
positive effects on skin by delaying or preventing skin aging 
manifestations (Brincat 2000; Sator et al 2004), understand-
ing the effects of estrogen on skin is complicated by a number 
of factors. Firstly, when interpreting the results of studies 
looking at the effects of estrogen on skin it is important to 
remember that few randomized trials have been carried out 
and that the majority of trials have been observational studies. 
The use of different estrogen preparations and doses with, or 
without, the concomitant use of progesterone or testosterone 
also complicates this issue. Progestagens are combined with 
estrogen compounds and given cyclically or continuously since 
estrogen therapy alone may result in endometrial hyperplasia. 
Estrogen monotherapy can be used following hysterectomy 
(Sator et al 2004). Thus, making true comparisons and judg-
ments of the isolated effects of estrogen are difﬁ  cult. Indeed, 
topical progesterone cream (2%) alone has been shown to 
increase skin elasticity and decrease wrinkling in peri- and 
post-menopausal women (Holzer et al 2005). 
Controversies surrounding the risks associated with the 
use of hormone therapy also complicate the issue. HRT 
was initially introduced to improve menopausal symptoms, 
reduce the risk of osteoporosis and was thought to reduce 
the risk of cardiovascular events (Stampfer et al 1991). How-
ever, a recent study has suggested that HRT may increase 
the risk of cardiovascular events (Grady et al 2002). It has 
also been reported that HRT may increase the risk of breast 
cancer (Rossouw et al 2002) and this has led to a signiﬁ  cant 
reconsideration of the risks and beneﬁ  ts of systemic HRT. In 
response to this, recommendations for the use of HRT have 
become more stringent and it is now generally accepted that 
HRT should only be used to relieve menopausal symptoms, 
in the short-term (Hall and Phillips 2004). This means that 
justifying the use of randomized clinical trials to assess the 
effects of systemic estrogen on skin is difﬁ  cult from a risk-
beneﬁ  t point of view. 
Despite the controversy that surrounds the use of HRT 
in post-menopausal women; many authors suggest that the 
beneﬁ  ts of HRT in skin necessitate the need for further 
studies of its effects, not only in skin, but in other organ 
systems (Draelos 2005; Naftolin 2005; Wolff et al 2005). 
Furthermore, as the visual effects that are seen in the skin 
following the menopause may physiologically mirror the 
internal effects in other tissues (bone, cardiovascular system, 
cancer), skin may represent an easily accessible model. The 
use of topical estrogen could also be considered, but again 
this requires further investigation to determine the optimal 
dose for local beneﬁ  ts, while ensuring that systemic effects 
are avoided (Verdier-Sevrain et al 2006).
Skin and aging
Although estrogen deficiency is associated with skin 
changes, intrinsic aging also affects skin physiology. Skin 
undergoes profound changes associated with aging. This 
is most apparent in the face and other sun-exposed areas. 
Aging is associated with a decrease in skin thickness due 
to atrophy of the epidermis, dermis and subcutaneous fat. 
This is associated with dryness, wrinkling and an increased 
incidence of proliferative lesions. In the epidermis, aging 
is associated with a decrease in epidermal thickness, ﬂ  at-
tening of the dermal papilla and a decrease in melanocyte 
and Langerhans cell density. Within the dermis, increasing 
age leads to reduced ﬁ  broblast activity, reduced collagen 
and hyaluronic acid content, more fragmented elastin ﬁ  bers 
and decreased vascularity (Ashcroft et al 1995). Aging skin 
has also been shown to have increased pro-enzyme MMP-2 
expression (Ashcroft et al 1997), suggesting that aged skin 
is primed for tissue breakdown. A number of environmental 
factors such as sun exposure and smoking also affect the rate 
at which skin changes. 
Mechanism of estrogen action
Estrogens are the terminal ligand in the biosynthetic pathway 
of gonadal steroid hormones and are synthesized from andro-
gens by the loss of the C-19 angular methyl group and the 
formation of an aromatic A ring by the aromatase complex 
(Payne and Hales 2004). Estrone is derived from androstene-
dione, whereas estradiol is formed from testosterone. Estrone 
and estradiol are interconvertable due to different isoenzymes 
of 17β-hydroxysteroid dehydrogenase (Labrie 2004). 
The principle source of estrogen biosynthesis is the ovary 
in females of reproductive age. In men, estradiol can be 
produced in peripheral tissues by the actions of aromatase 
on testosterone (Simpson 1998). Humans, along with some 
other primates are unusual in that the adrenal cortex secretes 
large quantities of adrenal androgens, including dehydro-
epiandrosterone (DHEA), which can then be converted into 
active steroids in peripheral tissues providing they have the 
appropriate enzymes (Labrie 2004). DHEA synthesized in the 
adrenal zona reticularis serves as the main precursor of active Clinical Interventions in Aging 2007:2(3) 289
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estrogens in post-menopausal women. Notwithstanding, 
the production of DHEA also decreases with age. Serum 
concentrations are low prior to puberty, reaching a peak in 
adulthood. However, throughout adult life, levels decline and 
by the 7th decade are reduced to only 10%–20% of the peak 
concentrations in both sexes (Parker et al 1997). Therefore, 
with aging the precursor steroids for peripheral estrogen 
biosynthesis are reduced.
Estrogen receptor: non-genomic signaling
While the best described mode of estrogen signaling is me-
diated via two related proteins (ERα and ERβ) that belong 
to the nuclear receptor superfamily (see below), a further 
level of complexity in estrogen signaling is now apparent 
due to studies demonstrating rapid effects in response to 
estrogens that cannot be attributed to signaling via the 
classical intracellular nuclear receptors and their genomic 
pathways (Levin 2002). These rapid effects, at rates much 
faster than can be attributed to genomic signaling, have led 
to the view that cell membrane forms of estrogen recep-
tors exist that are coupled to cytosolic signal transduction 
proteins able to initiate different signaling cascades via 
conventional second messengers (Nadal et al 2001). Es-
trogens have been shown to activate second messengers 
such as adenylate cyclase and cAMP (Aronica et al 1994), 
phospholipase C (Lieberherr et al 1993), protein kinase 
C (Marino et al 2002) and the mitogen-activated protein 
kinase (MAPK) (Shaul 1999; Russel et al 2000). Interest-
ingly, estrogen can also activate ligand or voltage-gated ion 
channels (Pappas et al 1995; Razandi et al 1999; Nadal et 
al 2001) resulting in the increase in levels of intracellular 
calcium (Benten et al 2001). 
The term "activators of nongenotropic estrogen-like 
signaling (ANGELS)” has been introduced to deﬁ  ne small 
nonphenolic molecules that mimic the nongenotropic ac-
tions of estrogens, but lack their classical genotropic ef-
fects (Kousteni et al 2003). ANGELS appear to represent a 
novel class of compounds that differ mechanistically from 
classical estrogens. One such compound is estren, which is 
completely devoid of classical genotropic actions (Kousteni 
et al 2003), but can reverse bone loss in sex steroid-deﬁ  cient 
mice (Kousteni et al 2002).
Classical mechanism of action: genomic signaling
Two distinct intracellular estrogen receptors (ERα and ERβ) 
have been identiﬁ  ed that belong to the superfamily family 
of nuclear hormone receptors (Moverare et al 2002). It is 
now clear that estrogens have important effects on many 
non-reproductive tissues and the expression of the two 
estrogen receptors is tissue dependent. In addition to the 
male and female reproductive tissues, ERα and ERβ are 
expressed in tissues as diverse as bone, brain, lung, bladder, 
thymus, pituitary, hypothalamus, heart, kidney, adrenal, the 
cardiovascular system and the skin including the hair follicle 
(reviewed in Thornton 2002, 2005).
The two estrogen receptors are distinct proteins encoded 
by separate genes that are located on different chromosomes 
(Enmark et al 1997). The ERα and ERβ proteins share 
approximately 97% homology in the DNA binding domain, 
with only a few amino acids differing in this region. However, 
in the ligand binding domain they only share 59% homology 
(Gustafsson 1999), while they share little homology in the amino 
terminal domain, hinge domain and COOH domain (Moverare 
et al 2002). With such a difference in the ligand binding domain, 
it could be anticipated that the receptors would bind estradiol 
with different afﬁ  nities; this however is not the case, since 
17β-estradiol has a similar afﬁ  nity for both receptors. Ligand 
binding analysis has shown an average dissociation constant of 
0.5 nM for 17β-estradiol on mouse ERβ and 0.2 nM on mouse 
ERα (Giguere 1998), suggesting ERβ has a slightly lower af-
ﬁ  nity for 17β-estradiol. Many synthetic estrogens also bind both 
receptors with a similar afﬁ  nity (Kuiper et al 1997). 
Similar to all intracellular steroid receptors, ERα and ERβ 
are ligand activated nuclear transcription factors that enhance 
target-gene transcription upon binding to chromatin. Activa-
tion of the target gene by 17β-estradiol activates both ERα 
and ERβ to increase transcriptional activities when dimers 
of the liganded receptors bind to estrogen response elements 
(ERE) which are speciﬁ  c DNA palindrome sequences located 
in the promoter region of estrogen-regulated target genes 
(Klinge 2001). Activation of transcription also requires the 
recruitment of a large coactivator complex composed of p160 
coactivators including GRIP1 and SRC-1 and the histone 
acetyltransferases p300/CREB-binding protein and pCAF 
(Webb et al 2003). While the DNA binding domain mediates 
ERE recognition, the mediation of coactivator recruitment 
occurs via distinct activation functions (AF) located in the 
N-terminal domain (AF-1) and the ligand binding domain 
(AF-2) (Figure 2). Coactivators are tissue-speciﬁ  c and there 
is some evidence that ERα and ERβ differ in their require-
ments for coactivators in a cell and tissue dependent manner 
(Smith and O’Malley 2004).
In addition to the well characterized mode of action 
via EREs, estrogen receptors may also interact with other 
transcription factors bound to their cognate DNA binding 
sites through protein-protein interactions. For example, both Clinical Interventions in Aging 2007:2(3) 290
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ERα and ERβ enhance the transcription of genes that contain 
AP-1 sites, the cognate binding site for the Jun/Fos complex 
(Paech et al 1997) (see Figure 3). ERα and ERβ can also 
enhance the transcription of genes that contain binding sites 
for other transcription factors (Elgort et al 1996). While the 
precise mechanism of ER action at AP-1 sites is still unclear, 
studies suggest that there are striking differences from ER 
action at EREs (Webb et al 1999).
Since ERα and ERβ are often co-localized within many 
tissues, it was assumed that they would exert their effects 
on different target genes. However, there is evidence that 
ERα and ERβ can form both homodimers and heterodimers 
and that ERα homodimers and ERα/ERβ heterodimers are 
formed in preference to ERβ homodimers (Cowley et al 
1997). It has been proposed that in a cell where both estrogen 
receptors are present, the overall estrogen responsiveness 
may be determined by the ERα:ERβ ratio (Stenn and Paus 
2001). Furthermore, where ERs are binding to AP-1 sites, 
binding of ERα or ERβ homodimers can have opposing ef-
fects on gene transcription (Paech et al 1997; Kushner et al 
Figure 2 Schematic representation of the modular structures of ERα and ERβ. The modular structure of the two estrogen receptors (ERα and ERβ)illustrating several 
distinct functional domains. The numbers within the ERα domains represent the percentage homology between the two receptors. There is little homology between activa-
tion function-1 (AF-1) in the N-terminal domain, whereas the core sequences of AF-2 in the ligand binding domain (LBD) are identical. The numbers above each receptor 
represent the amino acid position of each boundary. The DNA binding domain (DBD) shows the greatest degree of homology.
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Figure 3 Models of estrogen action at a classical estrogen response element (ERE) and an ER-dependent AP-1 response element. The stars represent the ligand bound to the 
estrogen receptor (ER). In the classical mode of action activated ERs bind as dimers to the ERE which is comprised of 2 inverted hexanucleotide repeats, and activates gene 
transcription. In a different mode of action, the ligand activated ER can mediate gene transcription via an AP-1 enhancer element that requires the AP-1 transcription factors 
Fos and Jun for transcriptional activation. The difference between the actions of the SERMs tamoxifen and raloxifene are due to their ability/inability to activate these path-
ways. Tamoxifen inhibits the transcription of genes regulated by the classical ERE, but activates the transcription of genes regulated by an AP-1 element. In contrast raloxifene 
does not have the ability to activate AP-1. Therefore there are numerous combinations by which SERMS can modulate the estrogen receptor in a tissue-speciﬁ  c manner. Clinical Interventions in Aging 2007:2(3) 291
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2000). Thus, this creates the possibility that ERα and ERβ 
can work antagonistically or synergistically (Matthews and 
Gustafsson 2003) . 
Selective estrogen receptor 
modulators (SERMs)
Clinically, estrogens are widely used in the form of both oral 
contraceptives and HRT. Although they are highly effective 
both as a contraceptive and managing menopausal symptoms 
in women, nevertheless the use of estrogens has also been 
implicated as a risk factor in breast and uterine cancer (Ros-
souw et al 2002). 
Tamoxifen is a non-steroidal triphenylethylene (Figure 4), 
which is widely used in the management of women with 
hormonally responsive early and metastatic breast cancer, 
since it acts as an antagonist of estrogen action in breast 
tissue (Cataliotti et al 2006). Although tamoxifen blocks 
estrogen action in breast cancer cells, conversely it stimulates 
proliferation of uterine cells by acting as an estrogen agonist, 
thereby resulting in an increase in the risk of endometrial 
cancer by three fold (Stygar et al 2003). 
The study of the selective biological effects of tamoxifen 
in different tissues has led to the embodiment of the con-
cept of selective estrogen receptor modulators or SERMs. 
SERMs bind to estrogen receptors and can act as either 
estrogen agonists or antagonists depending on the target 
tissue. Current SERMs generally act as agonists in liver, in 
bone by inhibiting bone resorption, and on the cardiovascular 
system by reducing the markers of cardiovascular risk such 
as LDL. They are often antagonists in tissues such as breast 
and brain, but exhibit a mixed response in the uterus (Jordan 
1998; Diel 2002). The undesirable uterine side-effects of 
tamoxifen have provided the drive for the development of 
the “ideal” SERM. 
More recently a new SERM, raloxifene has been 
introduced (Figure 4). Raloxifene is derived from a ben-
zothiophene series of anti-estrogens and is now approved 
for the prevention and treatment of osteoporosis in post-
menopausal women (reviewed in Neven and Vergotta 
2001). While raloxifene exhibits antiestrogen activity in 
the breast, in contrast to tamoxifen, it lacks uterotrophic 
activity and thus signiﬁ  es an improved agonist/antagonist 
proﬁ  le (Stygar et al 2003). 
Since the three-dimensional structure of tamoxifen and 
raloxifene differ to 17β-estradiol (Figure 4) binding of these 
ligands to the estrogen receptor in breast tissue results in a 
conformational change that blocks AF-2 activity. This results 
in differences in their ability to recruit essential co-activators, 
thus eliminating the estrogen effect (Sporn 2004). Although 
tamoxifen inhibits the transcription of genes that are regu-
lated by a classical ERE, tamoxifen activates the AP-1 target 
gene in uterine cells (Kushner 2000) in an AF-independent 
manner. Raloxifene, however, does not have the ability to 
activate AP-1 which would account for the differences seen 
in their effects on the uterus. This gives numerous combina-
tions by which SERMS can modulate estrogen receptors in a 
tissue-speciﬁ  c manner. Understanding why SERMs exhibit 
different estrogen activities will help to identity new SERMs 
with more favourable proﬁ  les.
Since hypoestrogenism has detrimental effects on 
many other tissues including the skeleton, the CNS and the 
Figure 4 Molecular structure of 17β-estradiol, tamoxifene and raloxifene.
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cardiovascular system, many consider the ideal SERM to have 
estrogenic activity in bone, the cardiovascular system, vagina 
and CNS, yet have antiestrogenic activity in the breast and 
uterus. However, since neither tamoxifen nor raloxifene pos-
sess this spectrum of properties, there is clearly a market for 
the development of speciﬁ  c SERMs to address these issues.
SERMs and skin biology
Despite the well documented effects of estrogen on skin 
physiology and aging, there is very limited data on the effect 
of SERMs on the skin. One of the adverse effects of tamoxi-
fen include hot ﬂ  ashes and vaginal dryness (reviewed in 
Neven and Vergotta 2001), but there have been no studies to 
determine effects on skin thickness, collagen content, elastic 
ﬁ  bers or the formation of wrinkles. A histopathological as-
sessment of rat skin following subcutaneous administration 
of tamoxifen observed that tamoxifen treatment resulted in 
the appearance of abnormal hair follicles, epidermal atrophy 
and increased dermal ﬁ  brosis, particularly around the hair 
follicles (Inaloz et al 2002). There have been reports of 
tamoxifen treatment causing diffuse thinning of the hair with 
moderate receding of the frontal hair line (Ayoub et al 1997) 
and the development of alopecia on the crown, which was 
reversed when treatment was stopped (Gateley and Bundred 
1997). Although alopecia is reported on the data and patient 
information sheet for proprietary tamoxifen, alopecia is not 
reported in the datasheets for the generic form of tamoxifen 
(Gateley and Bundred 1997). 
We have recently reported that tamoxifen alone has no 
effect on human hair shaft elongation in organ culture, sug-
gesting it is not an estrogen agonist (Nelson 2006). However, 
a 10-fold excess of tamoxifen incubated in combination 
with 17β-estradiol eliminated the inhibitory effect of 17β-
estradiol, suggesting that tamoxifen acts as an antagonist of 
estrogen in the female scalp hair follicle (Nelson 2006). 
Notwithstanding, there have been some studies that sug-
gest tamoxifen may be useful in the treatment of keloids. 
Tamoxifen has been shown to inhibit the proliferation of 
ﬁ  broblasts cultured from keloid biopsies, and to inhibit their 
contraction (Hu et al 1998). Keloid dermal ﬁ  broblasts have 
also been shown to secrete higher levels of TGF-β1 than fetal 
dermal ﬁ  broblasts, which can be counteracted by incubation 
with tamoxifen (Mikulec et al 2001). 
Together these provide evidence that tamoxifen may 
improve wound healing and improve dermal scarring. Cell 
migration is a key element of the wound healing process and 
a recent study has shown that estrogen and tamoxifen induce 
cytoskeleton remodeling and migration in endometrial cancer 
cells (Acconcia et al 2006). Another fundamental aspect of 
cutaneous wound healing is an increase in dermal ﬁ  broblast 
proliferation, and recent studies in our laboratory have shown 
that monolayers of human dermal ﬁ  broblasts that have been 
mechanically wounded in vitro demonstrate a signiﬁ  cantly 
increased rate of both migration and proliferation in response 
to 17β-estradiol (Stevenson et al 2005). Furthermore, we 
have recently demonstrated that the proliferative activity of 
mechanically wounded cultured human dermal ﬁ  broblasts 
is signiﬁ  cantly increased in the presence of tamoxifen and 
raloxifene (Figure 5), supporting the application of SERMs 
as potential therapeutic agents to improve wound healing. 
Other groups using cultured human dermal ﬁ  broblasts have 
shown that the levels of expression of ERα and ERβ can be 
modulated by 17β-estradiol, tamoxifen and raloxifene (Hac-
zynski et al 2004). Another study has shown that raloxﬁ  ne has 
a stronger positive stimulatory effect on collagen biosynthesis 
than 17β-estradiol (Surazynski et al 2003) and that in contrast 
to estradiol, raloxifene inhibits the expression of MMP-9. 
Tamoxifen has been used in clinical trials for patients with 
melanoma since the late 1970s. Initially it showed promise 
as a single agent and then was combined with chemotherapy 
in 1984 (Rusthoven 1998). Since then, a number of phase 
II clinical trials have combined tamoxifen with different 
chemotherapeutic agents with overall response rates rang-
ing from 8% to 60%. However, treatment of melanoma with 
tamoxifen still remains controversial, since it is still unclear 
whether the strength of evidence from the randomized trials 
outweighs the combined evidence from numerous nonran-
domized trials (Rusthoven 1998). 
In vitro, tamoxifen has also been shown to inhibit the 
proliferation of a melanoma cell line (SK-Mel–28) (Lama 
et al 1999). Cell attachment to plastic and invasion through 
ﬁ  bronection in vitro of the highly metastatic cutaneous mela-
noma cell line (A375-SM) is also reduced in the presence 
of tamoxifen (Dewhurst et al 1997). Others have shown that 
tamoxifen can induce cell death in malignant melanoma cell 
lines and this cytoxicity may be due to inactivation of the 
insulin-like growth factor receptor (IGF-1R) (Kanter-Lew-
ensohn et al 1999). Clearly, malignant melanomas and the 
derived cell lines may be heterogeneous and the actions of 
estrogens in these tissues is worthy of further study. 
Potential SERMs in development
Recently much emphasis has been placed on developing 
SERMS, which have tissue speciﬁ  c estrogen actions that 
can separate the positive biological effects from the un-
desirable ones. Several SERM trials are underway but are Clinical Interventions in Aging 2007:2(3) 293
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being evaluated in terms of traditional outcomes such as 
bone mineral density, breast and endometrial cancer, and 
cardiovascular risk. A number of compounds are currently 
undergoing Phase III clinical trials (http://www.clinicaltrials.
gov). These include lasofoxifene (Pﬁ  zer), arzoxifene (Lilly) 
and bazedoxifene (Wyeth) (see Figure 6). 
The safety and effectiveness of lasofoxifene in reducing 
new spinal fractures in women with osteoporosis is currently 
being investigated; (PEARL: Postmenopausal Evaluation 
And Risk-Reduction with Lasofoxifene). This study is 
expected to enroll 7500 women and the primary outcomes 
will investigate new radiographic vertebral fractures at 3 
years, while the secondary outcomes will compare clinical 
fractures, non-vertebral fractures, bone mineral density, 
breast cancer, cardiovascular events, and gynecological 
safety events at 3 years. 
Eli Lilly and Company is sponsoring a study of another 
SERM, arzoxifene, in a phase III clinical trial to determine 
its effects on bone mass and the uterus of postmenopausal 
women. This study will determine the effects of arzoxifene 
on bone mineral density at the spine and hip as well as the 
effects on the uterus. Secondary outcomes will include the 
effects of arzoxifene on blood tests that measure changes in 
bone rebuilding in postmenopausal women with low bone 
density; also the effects on blood lipids and other blood 
markers of heart disease and effects on breast density will 
be determined.
A third SERM in phase III clinical trial sponsored by Wy-
eth is bazedoxifene. The purpose of this study is to determine 
whether bazedoxifene/conjugated estrogens combinations are 
effective in the treatment of moderate to severe vasomotor 
symptoms associated with menopause and whether they are 
effective in the treatment of vaginal atrophy. The effective-
ness of bazedoxifene/conjugated estrogens combinations for 
the prevention of endometrial hyperplasia and osteoporosis 
in postmenopausal women is also under investigation. How-
ever, none of these studies have been designed to assess the 
effects of these SERMs in the skin and it’s appendages in 
the women studied.
Conclusion
Evident changes associated with skin aging are thinning of 
the skin, increased dryness and reduced vascularity. The 
protective function of the skin can become impaired and 
aging is also associated with impaired wound healing, hair 
loss and skin cancer. Clearly the skin is an important es-
trogen target tissue, yet we still do not fully understand the 
molecular processes involved and the mechanisms by which 
estrogens and related compounds regulate skin function and 
delay skin aging. The widespread and constant expression of 
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Figure 5  Tamoxifen and raloxifene increase the DNA synthesis of mechanically wounded human dermal ﬁ  broblasts in vitro. A 3H-thymidine assay was used to measure 
DNA synthesis in wounded dermal ﬁ  broblasts (n = 3) in the presence of 100 nM tamoxifen (black bar) and 100 nM raloxifene (white bar) and vehicle control (0.0001% 
absolute ethanol (hatched bar). All assays were performed in triplicate dishes. Data are presented as patient mean +/– SEM. * p < 0.05.Clinical Interventions in Aging 2007:2(3) 294
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new generation SERMs to prevent osteoporosis and reduce 
the incidence of cardiovascular disease in postmenopausal 
women, it is important to understand their effects on the skin 
and the hair follicle. 
Undesirable effects on the skin may lead to chronic 
wound healing or an increased incidence of skin cancer; in 
addition women ﬁ  nd the adverse occurrence of hair loss very 
distressing. Conversely, there may be SERMs currently in 
use or in development that may act as estrogen agonists in 
human skin and the hair follicle and may potentially provide 
a useful therapy for clinical application to delay the aging 
manifestations of the skin. However, research into the poten-
tial use of SERMs as a therapy for symptoms of skin aging 
appears to be very much in its infancy. 
In order to understand more comprehensively the mecha-
nism of estrogen action on skin aging, we need to improve 
our understanding of the complex interactions of estrogen 
signaling pathways. In addition to SERMs, new advances 
in the development of selective ligands for ERα and ERβ, 
and activators of nongenotrophic estrogen-like signaling 
(ANGELS) may also provide a basis for further interven-
tions in pathological processes that involve the impairment 
of estrogen action in human skin. This may have important 
implications for therapies for skin aging, hair growth, skin 
cancer and wound healing. 
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